Regardless, a phase I trial evaluating the anti-LAG-3 antibody “BMS 986016” is underway, assessing its efficacy alone and in combination with the anti-PD-1 antibody nivolumab in recurrent GBM patients (NCT02658981). The gene discussed is LAG3; the disease is glioblastoma.